XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Sees Significant Decline in Short Interest

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 3,369 shares, a decline of 93.9% from the March 15th total of 55,641 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 10,793 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Down 4.4%

Shares of XTLB stock opened at $2.37 on Friday. The stock has a market capitalization of $5.21 million, a PE ratio of -3.70 and a beta of 1.27. XTL Biopharmaceuticals has a 52-week low of $2.12 and a 52-week high of $10.28. The stock’s 50-day moving average price is $2.97 and its 200 day moving average price is $9.39.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.